- Home
- GTN vs ABVX Comparison
GTN vs ABVX Comparison
Compare GTN & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GTN
- ABVX
- Stock Information
- Founded
- GTN 1897
- ABVX 2013
- Country
- GTN United States
- ABVX France
- Employees
- GTN N/A
- ABVX N/A
- Industry
- GTN Broadcasting
- ABVX
- Sector
- GTN Industrials
- ABVX
- Exchange
- GTN Nasdaq
- ABVX Nasdaq
- Market Cap
- GTN 463.2M
- ABVX 511.3M
- IPO Year
- GTN N/A
- ABVX N/A
- Fundamental
- Price
- GTN $4.94
- ABVX $7.94
- Analyst Decision
- GTN Strong Buy
- ABVX Buy
- Analyst Count
- GTN 3
- ABVX 4
- Target Price
- GTN $6.17
- ABVX $31.50
- AVG Volume (30 Days)
- GTN 1.3M
- ABVX 252.6K
- Earning Date
- GTN 08-07-2025
- ABVX 08-11-2025
- Dividend Yield
- GTN 6.57%
- ABVX N/A
- EPS Growth
- GTN N/A
- ABVX N/A
- EPS
- GTN 2.34
- ABVX N/A
- Revenue
- GTN $3,603,000,000.00
- ABVX $11,444,012.00
- Revenue This Year
- GTN N/A
- ABVX $284.20
- Revenue Next Year
- GTN $14.83
- ABVX N/A
- P/E Ratio
- GTN $2.08
- ABVX N/A
- Revenue Growth
- GTN 9.08
- ABVX 128.98
- 52 Week Low
- GTN $2.91
- ABVX $4.77
- 52 Week High
- GTN $6.61
- ABVX $14.16
- Technical
- Relative Strength Index (RSI)
- GTN 71.27
- ABVX 65.58
- Support Level
- GTN $4.44
- ABVX $7.41
- Resistance Level
- GTN $4.67
- ABVX $8.13
- Average True Range (ATR)
- GTN 0.21
- ABVX 0.43
- MACD
- GTN 0.07
- ABVX 0.12
- Stochastic Oscillator
- GTN 98.66
- ABVX 92.21
About GTN Gray Television Inc.
Gray Media Inc is a multimedia company. The company owns and operates local television stations and digital assets. It also owns Gray Digital Media, a full-service digital agency offering national and local clients digital marketing strategies with digital products and services. Its additional media properties include video production companies Raycom Sports, Tupelo Media Group, and PowerNation Studios, and studio production facilities Assembly Atlanta and Third Rail Studios.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.